Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

February
14
2019

Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids

Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment. BOCA…

February
14
2019

Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radio Therapy to Treat Non-Melanoma Skin Cancers and Keloids

Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment. BOCA…

February
12
2019

Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare’s SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities

Data from this Non-Invasive, Highly Effective Treatment Option for Non-Melanoma Skin Cancer Published in Journal of Drugs in Dermatology BOCA RATON, Fla., Feb. 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company…

January
30
2019

Sensus Healthcare to Host Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call on February 14, 2019

BOCA RATON, Fla., Jan. 30, 2019 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy